MHRA clears catumaxomab for malignant ascites when standard cancer treatment has run out
The MHRA has approved catumaxomab for adults with malignant ascites when standard treatment of the underlying cancer is no longer feasible. The decision gives clinicians a new option for a complication that often forces repeated drainage procedures and drains time, comfort, and function from patients whose disease has already become difficult to control.
Malignant ascites is not a minor symptom. It is a fluid accumulation in the abdomen containing cancer cells, and in practice it can drive breathlessness, early satiety, pain, abdominal distension, and frequent procedural visits. For patients who have exhausted chemotherapy or cannot receive it safely, the therapeutic gap has been stark: drainage helps, but only temporarily. Catumaxomab is positioned in that gap, not as a cure for advanced cancer, but as a way to lengthen the interval before another paracentesis becomes necessary.
A bispecific antibody aimed at EpCAM-positive disease
Catumaxomab is a monoclonal antibody designed to bind epithelial cell adhesion molecule, or EpCAM, which is present on the surface of certain cancer cells, including those in ascitic fluid. The drug also activates immune cells, creating a bridge between the tumor target and the host immune response. In plain clinical terms, the treatment tries to recruit immune effector cells to attack malignant cells floating in the peritoneal cavity, a biologically plausible strategy in a compartment where standard systemic therapy may no longer be an option.
The route of administration matters here. Catumaxomab is given under the supervision of a doctor experienced in treating cancer, delivered through a catheter directly into the abdominal cavity as four infusions with escalating doses. Intraperitoneal delivery fits the disease biology: the target sits where the fluid accumulates, and local exposure may help concentrate activity where the burden is greatest.
Drainage-free intervals widened in the main study
A main clinical study enrolled 258 patients with malignant ascites and EpCAM-positive cancer who had no further chemotherapy options or for whom chemotherapy was unsuitable. Everyone in the comparison received paracentesis, the procedure used to drain abdominal fluid. The difference emerged after the procedure: patients who received catumaxomab after paracentesis did not require further drainage for around 46 days, compared with 11 days for patients treated with paracentesis alone.
One number captures the practical value of the drug. Four additional weeks without another drainage procedure can mean fewer hospital visits, less procedure-related discomfort, and more time away from the cycle of reaccumulating fluid. In a condition where the disease burden is often measured in days to the next intervention, prolonging the drainage-free interval is a clinically meaningful endpoint.
The choice of endpoint also makes sense. In malignant ascites, symptom control and procedure avoidance often matter more immediately than tumor shrinkage measured on imaging. Fluid reaccumulation is the bedside reality patients feel first, and the interval before repeat drainage is a direct marker of whether a treatment is doing something useful in everyday care.
Safety profile will require active monitoring
The approval comes with a familiar regulatory caution: catumaxomab will be kept under close safety and effectiveness review, as is the case with all licensed medicines. That caution is especially relevant because the immune mechanism that makes the drug attractive can also make it inflammatory.
Common side effects include nausea, vomiting, diarrhoea, abdominal pain, fever, chills, fatigue, and cytokine release syndrome. The last of these is particularly important. Cytokine release syndrome reflects brisk immune activation, and while it can be part of the intended pharmacology, it can also produce systemic symptoms that are difficult for frail patients with advanced cancer to tolerate. The balance between benefit and toxicity will depend heavily on patient selection, supportive care, and the judgment of clinicians experienced in cancer treatment.
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, framed the decision around burden and residual options. Malignant ascites can impose a considerable burden when further treatment options are limited, and the approval offers an additional treatment that may extend the time patients live without needing another drainage procedure. That is a modest but concrete clinical gain, particularly in a setting where palliative priorities often dominate the treatment plan.
Regulatory pathway and next steps for UK practice
The marketing authorisation was granted on 2 October to Atnahs Pharma UK Limited under the International Recognition Procedure. Product information will be published on the MHRA Products website within seven days of approval, including the Summary of Product Characteristics and Patient Information Leaflet. Those documents will determine how the drug is positioned in routine use, including any contraindications, monitoring requirements, and administration details beyond the summary provided in the approval notice.
For clinicians, the key question is not whether ascites can be drained — it can — but how often that cycle can be interrupted before it becomes an exhausting routine. Catumaxomab now enters that discussion as a locally delivered immunotherapy for EpCAM-positive malignant ascites in adults when standard cancer treatment is no longer feasible.
Patients and healthcare professionals are being encouraged to report suspected side effects through the MHRA Yellow Card scheme. Ongoing pharmacovigilance will be central, because the same immune activation that gives catumaxomab its rationale also creates the potential for inflammatory toxicity, and the real-world tolerability of repeated intraperitoneal infusions will determine how widely the drug is adopted in practice.